Recent research on immunotherapy for anti-N-methyl-D-aspartate receptor encephalitis.
抗N-甲基-D-天冬氨酸受体脑炎免疫治疗的研究进展.
Anti-N-methyl-D-aspartate receptor encephalitis
Bortezomib
Child
Immunotherapy
Rituximab monoclonal antibody
Journal
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
ISSN: 1008-8830
Titre abrégé: Zhongguo Dang Dai Er Ke Za Zhi
Pays: China
ID NLM: 100909956
Informations de publication
Date de publication:
15 Aug 2022
15 Aug 2022
Historique:
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
31
8
2022
Statut:
ppublish
Résumé
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a central nervous system disease characterized by neurological and psychiatric symptoms. Immunotherapy is the basic treatment for this disease, including first- and second-line therapies for the acute stage and the long-course therapy for the chronic stage. Anti-NMDAR encephalitis often has a good prognosis, but some patients may still have neurological dysfunction due to poor response to current immunotherapy. In addition, the adverse reactions and economic burden of drugs are practical problems in clinical practice. To solve the above problems, continuous improvements have been made in immunotherapy regimens in terms of dose, route of administration, and course of treatment, and some new immunotherapy drugs have emerged. This article reviews the recent research on immunotherapy for anti-NMDAR encephalitis. 抗N-甲基-D-天冬氨酸受体（N-methyl-D-aspartate receptor，NMDAR）脑炎是一种以神经及精神症状为主要表现的中枢神经系统疾病。免疫治疗是基础治疗，包括急性期的一线治疗和二线治疗，以及慢性期的长程治疗。抗NMDAR脑炎总体预后良好，但仍有部分患者对当前免疫治疗方案反应欠佳，遗留神经系统功能障碍。此外，药物的不良反应及经济负担也是临床工作中常遇到的现实问题。为解决上述问题，近年来免疫治疗方案在药物的剂量、使用途径、疗程方面不断改进，同时涌现出一些新免疫治疗药物。因此，该文就抗NMDAR脑炎免疫治疗的研究进展进行综述。.
Autres résumés
Type: Publisher
(chi)
抗N-甲基-D-天冬氨酸受体（N-methyl-D-aspartate receptor，NMDAR）脑炎是一种以神经及精神症状为主要表现的中枢神经系统疾病。免疫治疗是基础治疗，包括急性期的一线治疗和二线治疗，以及慢性期的长程治疗。抗NMDAR脑炎总体预后良好，但仍有部分患者对当前免疫治疗方案反应欠佳，遗留神经系统功能障碍。此外，药物的不良反应及经济负担也是临床工作中常遇到的现实问题。为解决上述问题，近年来免疫治疗方案在药物的剂量、使用途径、疗程方面不断改进，同时涌现出一些新免疫治疗药物。因此，该文就抗NMDAR脑炎免疫治疗的研究进展进行综述。.
Identifiants
pubmed: 36036136
pii: 1008-8830(2022)08-0948-06
doi: 10.7499/j.issn.1008-8830.2204021
pmc: PMC9425858
pii:
doi:
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
Types de publication
Journal Article
Review
Langues
eng
chi
Sous-ensembles de citation
IM
Pagination
948-953Références
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Neurotherapeutics. 2016 Oct;13(4):824-832
pubmed: 27215218
Trials. 2020 Jul 8;21(1):625
pubmed: 32641101
Neurol Neuroimmunol Neuroinflamm. 2019 Oct 16;7(1):
pubmed: 31619447
J Assoc Genet Technol. 2020;46(2):98-102
pubmed: 32526729
Eur J Paediatr Neurol. 2019 Jan;23(1):7-18
pubmed: 30318435
J Neuroimmunol. 2016 Oct 15;299:107-111
pubmed: 27725107
Eur J Paediatr Neurol. 2020 Nov;29:87-91
pubmed: 33046392
J Neurol. 2020 Aug;267(8):2462-2468
pubmed: 32535682
Neurotherapeutics. 2019 Jul;16(3):828-837
pubmed: 30868469
J Clin Apher. 2019 Jun;34(3):171-354
pubmed: 31180581
Front Neurol. 2020 Dec 22;11:602102
pubmed: 33414761
Br J Clin Pharmacol. 2013 Jan;75(1):45-59
pubmed: 22519685
Cancer Chemother Pharmacol. 2016 Oct;78(4):661-71
pubmed: 27646791
CNS Neurosci Ther. 2019 Jan;25(1):151-153
pubmed: 30345626
Int Immunopharmacol. 2005 Nov;5(12):1731-40
pubmed: 16102523
J Neurol Sci. 2021 Dec 15;431:120042
pubmed: 34740019
Chin Med J (Engl). 2018 Jan 20;131(2):156-160
pubmed: 29336363
J Neuroimmunol. 2021 May 15;354:577527
pubmed: 33652303
J Neurol. 2017 Apr;264(4):647-653
pubmed: 28154970
Clin Ther. 2019 Oct;41(10):2112-2136
pubmed: 31445679
J Neuroimmunol. 2021 Dec 15;361:577753
pubmed: 34739913
J Neurol Sci. 2017 Jun 15;377:127-132
pubmed: 28477682
Br J Haematol. 2019 Jul;186(2):207-219
pubmed: 30924130
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 22;8(5):
pubmed: 34301820
Ann Neurol. 2007 Jan;61(1):25-36
pubmed: 17262855
J Neuroimmunol. 2021 Mar 15;352:577479
pubmed: 33486307
Front Psychiatry. 2021 Mar 29;12:638901
pubmed: 33854451
J Neuroimmunol. 2021 Jul 15;356:577586
pubmed: 33975246
J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):757-768
pubmed: 33649022
Ann Clin Transl Neurol. 2018 Mar 23;5(5):598-605
pubmed: 29761122
Front Pediatr. 2021 Apr 22;9:605042
pubmed: 33968840
Ann Clin Transl Neurol. 2021 Apr;8(4):763-773
pubmed: 33609012
Ann Rheum Dis. 2021 Feb;80(2):137-139
pubmed: 33162396
Pediatr Neurol. 2018 Oct;87:82
pubmed: 30501890
Front Pediatr. 2021 Jun 29;9:691599
pubmed: 34268281
Pediatr Neurol. 2020 Feb;103:61-64
pubmed: 31759783
Chin Med J (Engl). 2020 Dec 14;134(12):1498-1499
pubmed: 33323814
Front Neurol. 2020 Dec 14;11:606923
pubmed: 33381080
Front Immunol. 2021 Dec 16;12:790962
pubmed: 34975890
Zhonghua Er Ke Za Zhi. 2019 Feb 2;57(2):125-130
pubmed: 30695887
Neurotherapeutics. 2016 Jan;13(1):147-62
pubmed: 26692392
J Neuroimmunol. 2019 May 15;330:81-86
pubmed: 30851542
Neurol Sci. 2019 Oct;40(10):2017-2030
pubmed: 31161339
Ann Clin Transl Neurol. 2019 Jul;6(7):1202-1213
pubmed: 31353868
Neurology. 2016 May 3;86(18):1683-91
pubmed: 27037228
Neurol Sci. 2021 Nov;42(11):4683-4696
pubmed: 33728548
J Neuroimmunol. 2021 Oct 15;359:577687
pubmed: 34364103
J Clin Apher. 2020 Apr;35(2):72-78
pubmed: 31899560
J Neurosci Nurs. 2019 Aug;51(4):194-197
pubmed: 31180943
Acta Neurol Belg. 2022 Jun;122(3):797-799
pubmed: 33689111
J Neuroimmunol. 2021 Jun 15;355:577565
pubmed: 33813318
Front Immunol. 2021 May 21;12:641106
pubmed: 34093529
Lancet Neurol. 2019 Nov;18(11):1045-1057
pubmed: 31326280
Acta Neurol Scand. 2020 Nov;142(5):449-459
pubmed: 32484900